Orchestra BioMed Holdings Profit Margin

Orchestra BioMed Holdings (OBIO) currently reports a profit margin of -185.4% as of June 2026. That compares with -2367.49% in the prior-year period — up 92.2% year over year. That is below the sector sector average of 21.49%. Use the charts on this page to explore Orchestra BioMed Holdings's profit margin history and peer comparisons.

Orchestra BioMed Holdings's profit margin increased from -2367.49% to -185.4% — a 92.2% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Orchestra BioMed Holdings's profit margin of -185.4% is lower than the its sector sector average of 21.49%. That is roughly 962.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Orchestra BioMed Holdings's current -185.4% should be judged against industry norms (sector average: 21.49%) and against OBIO's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -185.4%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 21.49%. From there, open related valuation or income-statement pages for Orchestra BioMed Holdings, and consider following OBIO for alerts when major investors trade the stock.